Edurne Berra got her Degree in Pharmacy at the University of Navarra (Pamplona, Spain) and a Licence Spéciale in Toxicology at the ULB (Brussels, Belgium). She started her research career, supervised by Dr J. Moscat at the CBM “Severo Ochoa” (Madrid, Spain), studying the signalling pathways triggered by the atypical PKC isotypes (PKCζ and λ). After a first postdoctoral at the Glaxo-Wellcome-CSIC laboratory of Molecular and Cell Biology (Madrid, Spain), Edurne moved to Dr J. Pouysségur’s lab (Nice, France) where she was appointed Chargé de Recherche (CNRS-CR1) and she got her HDR (Habilitation à la Direction de Recherche). In November 2007, Edurne joined CIC bioGUNE to lead her independent group, which is devoted to establish new players of the hypoxia signalling pathway, and to further translate this research to potential therapeutic applications in hypoxia related pathologies such as cancer.
Edurne has authored more than 50 scientific publications in highly prestigious journals (Cell, EMBO Journal, PNAS...) that received more than 7000 citations. Edurne has been awarded the Fundación Renal “Iñigo Alvarez de Toledo” Prize (2007), the “Dr Joseph Amalrich” Prize for Excellence in Cancer Research (2002) and the HFSP (1999) and EMBO (1998) Fellowships. Edurne is member of the Spanish Society for Biochemistry and Molecular Biology (SEBBM), the Spanish Society for Cancer Research (ASEICA) and the European Association for Cancer Research (EACR), and she is on the committee of the Spanish and the European Hypoxia Network
Latest Publications
2019
2017
2016
2015
2014
2013
2012
2008
2017
The research in the Carracedo lab is aimed at deconstructing the essential requirements of cancer cells with special emphasis on the translation of the acquired knowledge from bench to bedside. In order to define the genuine features of cancer cells, we focus on the signalling and metabolic alterations in prostate and breast cancer. Through the use of a hierarchical approach with increasing complexity, we work on cell lines and primary cultures (using cell and molecular biology technologies), mouse models of prostate cancer that are faithful to the human disease and the analysis of human specimens through the development of prospective and retrospective studies. Our work stems from the hypothesis that cancer is driven by signalling and metabolic alterations that, once identified, can be targeted for therapy. The center and our collaborator institutions offer state-of-the-art technologies (from OMICS to in vivo imaging), which allow us to build and answer our hypotheses with high level of confidence.
To address our scientific questions in cancer, the Carracedo lab has developed a series of research lines:
- Bioinformatics-based discovery. The lab takes full advantage on publicly available human prostate and breast cancer datasets in order to identify candidate genes to contribute to cancer pathogenesis, progression and response to therapy. Best hits are then validated employing genetic mouse models, xenograft surrogate assays and the latest advances in cellular and molecular biology combined with OMICs technologies.
- Genetic mouse models as a source for the identification of novel cancer players. Genetically engineered mouse models (GEMMs) can faithfully recapitulate many aspects of human cancer. Dr. Carracedo envisions the molecular analysis of GEMMs with high throughput technologies as a mean to identify novel cancer-related genes. These hits are then validated through the analysis of human cancer specimens and cellular and molecular biology approaches.
- Multi-OMICs analysis for non-invasive biomarker identification. Biofluids are the perfect source for cancer biomarkers that can inform about the presence or features of cancer. The lab has undertaken a biomarker discovery approach by applying the latest OMICs technologies to biofluid specimens from well-annotated prostate cancer patients, in order to define better molecules that inform about this disease.
-
Principal Investigator
Arkaitz Carracedo
-
Alice Macchia
-
Ana Talamillo
-
Ianire Astobiza
-
Laura Camacho
-
Natalia Martín Martín
-
Amaia Arruabarrena Aristorena
-
Isabel Mendizabal
-
Jana Crespo Trives
-
Verónica Torrano
-
Kathrin Keim
-
Amaia Zabala Letona
-
Ariane Schaub
-
Amaia Ercilla Eguiarte
-
Ana R Cortazar
-
Lucía Fadón
-
Onintza Carlevaris
-
Laura Martínez Pérez
-
Sonia Fernández Ruiz
-
Cristina Viera Bardon
-
Ainara Martinez Gonzalez
-
Pilar Castellnou Arenas
-
Mikel Pujana Vaquerizo
-
Laura Bozal Basterra
Members
Latest Publications
Phosphoinositide 3-Kinase-Regulated Pericyte Maturation Governs Vascular Remodeling
Figueiredo, AM;Villacampa, P;Dieguez-Hurtado, R;Lozano, JJ;Kobialka, P;Cortazar, AR;Martinez-Romero, A;Angulo-Urarte, A;Franco, CA;Claret, M;Aransay, AM;Adams, RH;Carracedo, A;Graupera, M
CIRCULATION
2020-08-18
LUZP1, a novel regulator of primary cilia and the actin cytoskeleton, is a contributing factor in Townes-Brocks Syndrome
Bozal-Basterra, L;Gonzalez-Santamarta, M;Muratore, V;Bermejo-Arteagabeitia, A;Da Fonseca, C;Barroso-Gomila, O;Azkargorta, M;Iloro, I;Pampliega, O;Andrade, R;Martin-Martin, N;Branon, TC;Ting, ...
ELIFE
2020-06-18
H-1 NMR-Based Urine Metabolomics Reveals Signs of Enhanced Carbon and Nitrogen Recycling in Prostate Cancer
Bruzzone, C;Loizaga-Iriarte, A;Sanchez-Mosquera, P;Gil-Redondo, R;Astobiza, I;Diercks, T;Cortazar, AR;Ugalde-Olano, A;Schafer, H;Blanco, FJ;Unda, M;Cannet, C;Spraul, M;Mato, JM;Embade, N;Carracedo, ...
JOURNAL OF PROTEOME RESEARCH
2020-06-05
Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer
Hermanova, I;Zuniga-Garcia, P;Caro-Maldonado, A;Fernandez-Ruiz, S;Salvador, F;Martin-Martin, N;Zabala-Letona, A;Nunez-Olle, M;Torrano, V;Camacho, L;Lizcano, JM;Talamillo, A;Carreira, S;Gurel, ...
JOURNAL OF EXPERIMENTAL MEDICINE
2020-06-01
OZF is a Claspin-interacting protein essential to maintain the replication fork progression rate under replication stress
Feu, S;Unzueta, F;Llopis, A;Semple, JI;Ercilla, A;Guaita-Esteruelas, S;Jaumot, M;Freire, R;Agell, N
FASEB JOURNAL
2020-05-01
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo
Alajati, A;D'Ambrosio, M;Troiani, M;Mosole, S;Pellegrini, L;Chen, JJ;Revandkar, A;Bolis, M;Theurillat, JP;Guccini, I;Losa, M;Calcinotto, A;De Bernardis, G;Pasquini, E;D'Antuono, R;Sharp, ...
JOURNAL OF CLINICAL INVESTIGATION
2020-05-01
Multiplex SERS Detection of Metabolic Alterations in Tumor Extracellular Media
Plou, J;Garcia, I;Charconnet, M;Astobiza, I;Garcia-Astrain, C;Matricardi, C;Mihi, A;Carracedo, A;Liz-Marzan, LM
ADVANCED FUNCTIONAL MATERIALS
2020-03-05
The Urinary Transcriptome as a Source of Biomarkers for Prostate Cancer
Sole, C;Goicoechea, I;Goni, A;Schramm, M;Armesto, M;Arestin, M;Manterola, L;Tellaetxe, M;Alberdi, A;Nogueira, L;Roumiguie, M;Lopez, JI;Jaka, JPS;Urruticoechea, A;Vergara, I;Loizaga-Iriarte, ...
CANCERS
2020-02-22
Physiological Tolerance to ssDNA Enables Strand Uncoupling during DNA Replication
Ercilla, A;Benada, J;Amitash, S;Zonderland, G;Baldi, G;Somyajit, K;Ochs, F;Costanzo, V;Lukas, J;Toledo, L
CELL REPORTS
2020-02-18
HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis.
Palomo-Irigoyen, Marta; Perez-Andres, Encarni; Iruarrizaga-Lejarreta, Marta; Barreira-Manrique, Adrian; Tamayo-Caro, Miguel; Vila-Vecilla, Laura; Moreno-Cugnon, Leire; Beitia, Nagore; Medrano, ...
journal of clinical investigation
2020-01-15